Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03782701 · ClinicalTrials.gov registry record · Phase 4
The Effect of Lumify™ Eyedrops on Eyelid Position
A Phase 4 study of Eyelid Droop, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03782701: Completed Phase 4 study of Eyelid Droop, sponsored by University of Miami.
NCT03782701 is a Phase 4 study of Eyelid Droop that has completed, run by University of Miami. The registered enrollment target is 43 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03782701, a Phase 4 study of Eyelid Droop, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the research is to see if Lumify™ has an effect on eyelid position.
Primary Outcome
Objective measurement of distance between inner margin of upper and lower eyelids from clinical photographs.
Conditions Studied
Interventions
- DRUG Brimonidine tartrate ophthalmic solution 0.025%
- OTHER Sterile balanced saline solution
Study Locations (1)
Florida
- Bascom Palmer Eye Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-06-18 |
| Est. Completion | 2020-04-01 |
| Phase | Phase 4 |
What the finished NCT03782701 record still lists
NCT03782701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Eyelid Droop appearing as the primary indexed condition, and to 2 interventions - of which Brimonidine tartrate ophthalmic solution 0.025% is the first listed.
NCT03782701 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03782701 about?
NCT03782701 is a clinical study titled "The Effect of Lumify™ Eyedrops on Eyelid Position". The purpose of the research is to see if Lumify™ has an effect on eyelid position.
What is the current status of trial NCT03782701?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2019-06-18. Estimated completion is 2020-04-01.
What conditions does trial NCT03782701 study?
This clinical trial studies the following conditions: Eyelid Droop.
What interventions are being tested in trial NCT03782701?
The interventions under investigation include: Brimonidine tartrate ophthalmic solution 0.025% (DRUG), Sterile balanced saline solution (OTHER).
Who is sponsoring clinical trial NCT03782701?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03782701 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eyelid Droop
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03782701's enrollment target sits among peer trials
43 1371st of 2000 higher than 621 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI